In 2007 the Dutch DESFonds (DES Fund) starts payment to victims of exposure to diethylstilbestrol in a collective settlement. This is unique in the world because the arrangement covers the entire range of DES-related disorders and individual persons do not have to start an expensive and emotionally taxing legal procedure with uncertain outcome, which would last several years. Individuals can now be compensated based on medical evidence of DES exposure and the presence of a DES-related disorder covered by the settlement. In close collaboration with the DES Centre (an association of DES victims) a careful procedure was followed before this settlement was realised. The Dutch Expert Committee on DES-related Health Effects first reviewed the literature for evidence and established a list of disorders with a causal association with DES. For each DES-related disorder covered by the settlement, the appropriate compensation was determined by the attributive risk and the severity of the disease. The settlement is the result of close collaboration between all parties involved.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Phenotype and Clinical Outcomes in Desmin-Related Arrhythmogenic Cardiomyopathy.
JACC Clin Electrophysiol
June 2024
Department of Cardiology, Virgen de las Nieves University Hospital, Granada, Spain; Instituto de Investigación Biosanitaria. ibs.GRANADA, Granada, Spain. Electronic address:
Background: Desmin (DES) pathogenic variants cause a small proportion of arrhythmogenic cardiomyopathy (ACM). Outcomes data on DES-related ACM are scarce.
Objectives: This study sought to provide information on the clinical phenotype and outcomes of patients with ACM caused by pathogenic variants of the DES gene in a multicenter cohort.
Risk factor assessment of digital eye strain during the COVID-19 pandemic: a cross-sectional survey.
Med Hypothesis Discov Innov Ophthalmol
December 2022
Department of Ophthalmology, Faculty of Medicine, Cairo University, Cairo, Egypt.
Background: Shifting to online learning during the coronavirus pandemic has increased the number of individuals symptomatic of digital eye strain (DES). This study aimed to determine the frequency and potential risk factors of DES among university staff members and students in this pandemic era.
Methods: A cross-sectional online survey was conducted during the pandemic, in May and June 2020.
Dry eye symptom questionnaires show adequate measurement precision and psychometric validity for clinical assessment of vision-related quality of life in glaucoma patients.
PLoS One
March 2023
Department of Optometry and Vision Science, School of Allied Health Sciences, College of Health and Allied Sciences, University of Cape Coast, Cape Coast, Ghana.
Purpose: To ascertain the presence of Dry Eye Syndrome (DES) in patients being treated for glaucoma, using subjective and objective methods and to examine DES impact on their quality of life (QOL).
Method: A cross-sectional study was conducted by employing 156 glaucoma patients recruited from treatment centers in the Cape Coast Metropolis in Ghana. All the participants underwent dry eye examination and completed the 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ), the Dry Eye-related Quality of Life Score (DEQS) and the Ocular Surface Disease Index (OSDI).
Optimized combined low level light therapy and intense pulsed light therapy for the treatment of dry eye syndrome caused by Meibomian glands dysfunction.
J Fr Ophtalmol
December 2022
Faculty of Medicine, Saint Joseph University, Beirut, Lebanon; Department of Ophthalmology, Hôtel-Dieu de France Hospital, Beirut, Lebanon; Beirut Eye Specialist Hospital, Beirut, Lebanon.
Dry eye syndrome (DES) is a common disease that can lead to ocular discomfort, reduced visual acuity and reduced quality of life. Meibomian Gland dysfunction plays an important role in most cases. To evaluate the effects of "EyeLight", a novel device delivering combined intense pulsed light (IPL) and low-level light therapy (LLLT), we conducted a retrospective chart review of patients refractory to conventional medical treatment who were treated with "EyeLight" therapy at Laser Vision, Lebanon.
View Article and Find Full Text PDFSirolimus-coated balloon versus everolimus-eluting stent in de novo coronary artery disease: Rationale and design of the TRANSFORM II randomized clinical trial.
Catheter Cardiovasc Interv
October 2022
Fondazione Ricerca e Innovazione Cardiovascolare, Milan, Italy.
Background: Percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation is a widely adopted strategy for the treatment of de novo coronary artery disease. DES implantation conveys an inherent risk for short- and long-term complications, including in-stent restenosis and stent thrombosis. Drug-coated balloons are emerging as an alternative approach to fulfill the "leaving nothing behind" principle and avoid long-term DES-related complications.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!